Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) (ERLOPET)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by Lung Cancer Group Cologne.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by:
Lung Cancer Group Cologne
ClinicalTrials.gov Identifier:
NCT00568841
First received: December 5, 2007
Last updated: September 16, 2009
Last verified: September 2009